Regenerative medicine company Orthocell Ltd (ASX:OCC, OTC:ORHHF) will release its quarterly results for the period ended June 30, 2026, on Monday, July 13, 2026.
The company will also host an investor webinar on Tuesday, July 14, 2026, providing an overview of the results and an operational update, including progress on the US rollout of Remplir and other strategic initiatives.
The webinar will be presented by Orthocell chair John Van Der Wielen, CEO and managing director Paul Anderson, CFO Jim Piper and VP U.S. Sales John Walker.
Investor Briefing – Webinar
When: 9.00am AWST | 11.00am AEDST Tuesday 14 July 2026
Register Now: Click to Register
Orthocell appoints Thai distributor for Remplir nerve repair rollout
No doubt part of the discussion will focus on recent appointment of MediTime as the exclusive in-country distributor for OCC's nerve repair product Remplir™ in Thailand, opening a commercial pathway into a nerve repair market estimated at about US$84 million.
The appointment follows regulatory approval from the Thai Food and Drug Administration in CY25, allowing Orthocell to begin commercialising Remplir in Thailand.
MediTime’s appointment also builds on Orthocell’s existing relationship with Device Technologies Group, which already supports Remplir distribution in Australia, New Zealand and Singapore.
Orthocell managing director Paul Anderson said the agreement marked an important step in the company’s Asian commercialisation strategy for Remplir.